biote corp - BTMD

BTMD

Close Chg Chg %
2.36 -0.02 -0.85%

Closed Market

2.34

-0.02 (0.85%)

Volume: 76.98K

Last Updated:

Jun 5, 2026, 4:00 PM EDT

Company Overview: biote corp - BTMD

BTMD Key Data

Open

$2.38

Day Range

2.33 - 2.38

52 Week Range

1.27 - 4.75

Market Cap

$71.58M

Shares Outstanding

30.33M

Public Float

27.64M

Beta

1.66

Rev. Per Employee

N/A

P/E Ratio

5.24

EPS

$0.50

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

227.57K

 

BTMD Performance

1 Week
 
17.00%
 
1 Month
 
7.34%
 
3 Months
 
24.80%
 
1 Year
 
-38.90%
 
5 Years
 
-76.00%
 

BTMD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About biote corp - BTMD

biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. It delivers a comprehensive, end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support. The company was founded in 2012 and is headquartered in Irving, TX.

BTMD At a Glance

biote Corp.
1875 West Walnut Hill Lane
Irving, Texas 75038
Phone 1-844-604-1246 Revenue 192.22M
Industry Hospital/Nursing Management Net Income 27.05M
Sector Health Services Employees 223
Fiscal Year-end 12 / 2026
View SEC Filings

BTMD Valuation

P/E Current 5.244
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 3.525
Price to Sales Ratio 0.496
Price to Book Ratio N/A
Price to Cash Flow Ratio 2.71
Enterprise Value to EBITDA 4.855
Enterprise Value to Sales 1.081
Total Debt to Enterprise Value 0.618

BTMD Efficiency

Revenue/Employee 861,968.61
Income Per Employee 121,278.027
Receivables Turnover 25.038
Total Asset Turnover 1.672

BTMD Liquidity

Current Ratio 1.215
Quick Ratio 0.784
Cash Ratio 0.536

BTMD Profitability

Gross Margin 69.759
Operating Margin 20.353
Pretax Margin 19.553
Net Margin 14.07
Return on Assets 23.519
Return on Equity N/A
Return on Total Capital 38.70
Return on Invested Capital 62.171

BTMD Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 183.767
Total Debt to Total Assets 119.337
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 147.504
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Biote Corp - BTMD

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
164.96M 185.36M 197.19M 192.22M
Sales Growth
+18.34% +12.37% +6.38% -2.52%
Cost of Goods Sold (COGS) incl D&A
56.77M 60.87M 61.70M 58.13M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.44M 2.99M 3.57M 3.67M
Depreciation
1.40M 800.00K 800.00K 1.20M
Amortization of Intangibles
1.03M 2.19M 2.77M 2.47M
COGS Growth
+16.30% +7.22% +1.37% -5.80%
Gross Income
108.18M 124.49M 135.49M 134.09M
Gross Income Growth
+19.43% +15.07% +8.83% -1.03%
Gross Profit Margin
+65.58% +67.16% +68.71% +69.76%
2022 2023 2024 2025 5-year trend
SG&A Expense
168.91M 81.27M 94.10M 94.97M
Research & Development
- - - -
-
Other SG&A
168.91M 81.27M 94.10M 94.97M
SGA Growth
+5.32% -51.89% +15.79% +0.93%
Other Operating Expense
- - - -
-
Unusual Expense
(66.45M) 36.97M 29.38M (9.05M)
EBIT after Unusual Expense
5.73M 6.26M 12.01M 48.17M
Non Operating Income/Expense
1.07M (16.00K) 11.00K 1.27M
Non-Operating Interest Income
- - - 900.00K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
5.09M 6.36M 11.00M 11.86M
Interest Expense Growth
-35.43% +24.99% +72.89% +7.82%
Gross Interest Expense
5.09M 6.36M 11.00M 11.86M
Interest Capitalized
- - - -
-
Pretax Income
1.71M (123.00K) 1.02M 37.58M
Pretax Income Growth
+102.70% -107.18% +926.02% +3,599.21%
Pretax Margin
+1.04% -0.07% +0.52% +19.55%
Income Tax
388.00K 2.68M 970.00K 5.99M
Income Tax - Current - Domestic
1.13M 1.94M 3.85M 2.01M
Income Tax - Current - Foreign
5.00K 17.00K 14.00K 4.00K
Income Tax - Deferred - Domestic
(743.00K) 721.00K (2.90M) 3.97M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.32M (2.81M) 46.00K 31.60M
Minority Interest Expense
2.29M (6.12M) (3.11M) 4.55M
Net Income
(969.00K) 3.32M 3.16M 27.05M
Net Income Growth
+85.31% +442.21% -4.79% +756.67%
Net Margin Growth
-0.59% +1.79% +1.60% +14.07%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(969.00K) 3.32M 3.16M 27.05M
Preferred Dividends
- - - -
-
Net Income Available to Common
(969.00K) 3.32M 3.16M 27.05M
EPS (Basic)
-0.1202 0.129 0.0921 0.8645
EPS (Basic) Growth
+86.20% +207.32% -28.60% +838.65%
Basic Shares Outstanding
8.06M 25.71M 34.27M 31.28M
EPS (Diluted)
-0.1202 0.129 0.0921 0.7376
EPS (Diluted) Growth
+86.20% +207.32% -28.60% +700.87%
Diluted Shares Outstanding
8.06M 25.71M 34.27M 36.67M
EBITDA
(58.28M) 46.22M 44.96M 42.79M
EBITDA Growth
- +179.29% -2.71% -4.83%
EBITDA Margin
-35.33% +24.93% +22.80% +22.26%

Snapshot

Average Recommendation BUY Average Target Price 2.986
Number of Ratings 5 Current Quarters Estimate 0.023
FY Report Date 06 / 2026 Current Year's Estimate 0.283
Last Quarter’s Earnings 0.06 Median PE on CY Estimate N/A
Year Ago Earnings 0.74 Next Fiscal Year Estimate 0.363
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 4 4
Mean Estimate 0.02 0.07 0.28 0.36
High Estimates 0.07 0.12 0.49 0.57
Low Estimate -0.02 0.01 0.11 0.16
Coefficient of Variance 167.77 75.90 61.81 59.99

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 4
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Biote Corp in the News